Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, including the nation’s leading ophthalmology pharmaceutical compounding business, ImprimisRx. The company holds large equity positions in Eton Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals, Mayfield Pharmaceuticals and Radley Pharmaceuticals, companies founded as subsidiaries of Harrow Health. The Company also owns royalty rights in certain 505(b)(2) drug candidates being developed by Eton, Surface, Melt, Mayfield and Radley. Harrow intends to create, invest in and grow paradigm shifting health care businesses that put patients first. Source
No articles found.
We are a leading science and technology company that delivers life-transforming me...
We are a leading science and technology company...
EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company committed ...
EyePoint Pharmaceuticals, Inc. is a specialty b...
Magellan Health, Inc., a Fortune 500 company, is a leader in managing the fastest ...
Magellan Health, Inc., a Fortune 500 company, i...
We are a clinical-stage biopharmaceutical company committed to realizing the promi...
We are a clinical-stage biopharmaceutical compa...
Sol-Gel is a clinical-stage specialty pharmaceutical company focused on developing...
Sol-Gel is a clinical-stage specialty pharmaceu...
Join the National Investor Network and get the latest information with your interests in mind.